粘液脆病房份额，规模，趋势，行业分析报告;通过诊断（计算断层扫描，MRI，组织活检）;通过治疗（手术，抗真菌药物，两性霉素B治疗，其他）;通过最终使用;按地区;分部预测，2021 - 2028

Report Summary

全球黏膜市场在2020年的价值为422.7百万美元，预计预测期内的CAGR增长3.4％。真菌感染患病率的激增，各种毒品的可用性，免疫疾病的发病率上升，冠状病毒的出现是推动市场增长的一些因素。此外，公众对真菌感染的公众意识提高，增加了对研发的政府资金进一步推动了市场增长。

Know more about this report:请求样本页面

The global mucormycosis market will be mainly driven by the emergence of the COVID-19 pandemic during the forecast period. Other factors that may contribute to the growth of the market include a rapid rise in hematological cancers and bone marrow transplants.

Covid-19大流行的出现增加了发展粘液霉病的风险。在大流行之前，这种真菌感染很少见，全球发病率每年仅为每10,000人每年0.06。Covid-19在全球造成巨大的医疗保健挑战。yabo娱乐vipCovid-19被截至5月2011年5月2011年的全球人士检测到。美国，印度和巴西是由于大流行受影响最严重的国家。

在美国，仅在3300万人受到疾病的影响到目前为止。印度正面临最差的第二波浪潮，每天检测到4，000例，这是从大流行开始的任何国家的案件最多。Covid-19日益增加的病例将显着增加全球市场粘液病例的数量。

行业动态

增长司机
The pandemic has an increased risk of mucormycosis as COVID-19 patients are immune-compromised by the use of certain drugs used in viral treatment. Typically, steroids and other antiviral drugs are used in the treatment which will significantly impact the immune system of the patient. Steroid treatment will also increase the blood glucose levels in corona patients which will make them more susceptible to mucormycosis.

Some of the hospitals in India are treating 200 mucormycosis patients and some of the regions in the Indian state of Maharashtra have seen a 100%-200% rise in mucormycosis cases during the second wave of the pandemic in the market.

粘膜霉病将导致失明，器官功能障碍以及有时需要手术治疗的其他问题。世界某些地方粘液19例患者的指数增加将是全球市场在预测期间增长的主要因素。

其他重要的市场因素将有助于全球粘液衰落市场，包括器官和骨髓移植的增加以及生长血液癌病例和糖尿病患者，因为这些人的免疫系统疲软。

全球近似0.45万人每年被诊断出白血病。目前，4.63亿糖尿病患者在世界范围内生活，预计将达到5.78亿，到2030年。因此，未来几年，人们发展的人们也将增加。

正在引入新的药物和诊断程序，用于治疗和诊断感染。2019年9月，美国FDA通过AMPlyx Pharmaceutical授予Fosmanogepix（APX001）的静脉内（IV）和口头配方的快速轨道指定。

It is approved the treatment of seven indications that include mucormycosis. Pfizer Inc. in association with its partner Basilea Pharmaceutica Ltd launched Cresemba (isavuconazole) in Taiwan, in 2020. The drug is used in mucormycosis and invasive aspergillosis.

粘液衰落市场研究范围

该市场主要是在诊断，治疗，终用用途和地区进行分段。

通过诊断	By Treatment	By End-Use	By Region
Computed Tomography (CT) Magnetic Resonance Imaging (MRI) Tissue Biopsy 其他	Surgery Antifungal Drugs Amphotericin B Therapy 其他	Hospitals & Clinics Medical Institutes Research Organization 其他	North America (U.S., Canada) Europe (France, Germany, Italy, Spain, UK, Netherlands, Austria) Asia Pacific (China, India, Japan, Indonesia, Malaysia, South Korea) 拉丁美洲（阿根廷，巴西，墨西哥） 中东和非洲（以色列，沙特阿拉伯，阿联酋，南非）

Know more about this report:请求样本页面

治疗洞察力

The market on the basis of treatment is segmented into antifungal drugs, amphotericin therapy, and others. The antifungal drugs market segment is further categorized into Posaconazole, Fluconazole, Isavuconazole, Voriconazole, Flucytosine, and Others.

Antifungal drugs and amphotericin B therapy are mostly used for the treatment. The only approved antifungal therapy for mucormycosis is amphotericin B (AMB) preparations, of which liposomal AMB (L-AMB) is commonly used in Europe as the standard of treatment.

地理概述

North America is expected to be the biggest market for mucormycosis owing to the increase in COVID-19 cases along with an increase in the cases of diabetic people and hematological cancer. Nearly, 35 million people are affected by diabetes and approximately 1,78,000 people were diagnosed with hematological cancer. The improved healthcare has led to many transplantation procedures and nearly 5,000 bone marrow transplantations are conducted in the U.S. every year.

预计亚太地区预测期间将成为增长最快的市场。Covid-19的越来越大的情况导致印度国家粘膜霉菌病例的前所未有的增加。艾滋病毒病例也更多地在东南亚地区和印度中有21万人是全球第三次艾滋病毒影响的国家。

Competitive Insight

Companies are focusing to develop new drugs and methods to diagnose mucormycosis owing to the emergence of the COVID-19 pandemic. Major market players are entering into partnerships and collaborations for the distribution of their drugs globally.

Some of the major market players operating in the market for mucormycosis include Biocon Limited, Abbott Laboratories, Cadila Pharmaceuticals Limited, F. Hoffman La Roche, Novartis AG, Merck Sharp and Dohme, Bristol Myers Squibb, Mylan Labs, Bayer AG, Sanofi, Lonza Group, Johnson & Johnson, Gilead Sciences and Pfizer Inc.